Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
2021 · Blood Advances · 107 citations
https://doi.org/10.1182/bloodadvances.2020003159
R
Ramy Rahmé
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
45
Papers
1.1K
Citations
13
h-index
14
i10-index
Ramy Rahmé is an academic researcher from Université Sorbonne Paris Nord. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Retinoids in leukemia and cellular processes & Chronic Myeloid Leukemia Treatments. The author has an h-index of 13, co-authored 39 publications.
ORCID: 0000-0002-3875-767XPapers by this author
worksOutcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
2020 · Leukemia · 50 citations
https://doi.org/10.1038/s41375-020-0758-4
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
2024 · Blood Advances · 14 citations
https://doi.org/10.1182/bloodadvances.2024014279
Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type
2025 · EMBO Reports · 1 citations
https://doi.org/10.1038/s44319-025-00375-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat